MD3416631T2 - Agenți terapeutici pentru bolile neurodegenerative - Google Patents
Agenți terapeutici pentru bolile neurodegenerative Download PDFInfo
- Publication number
- MD3416631T2 MD3416631T2 MDE20190027T MDE20190027T MD3416631T2 MD 3416631 T2 MD3416631 T2 MD 3416631T2 MD E20190027 T MDE20190027 T MD E20190027T MD E20190027 T MDE20190027 T MD E20190027T MD 3416631 T2 MD3416631 T2 MD 3416631T2
- Authority
- MD
- Moldova
- Prior art keywords
- neurodegenerative diseases
- therapeutic agents
- leucine
- acetyl
- administration
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3416631T2 true MD3416631T2 (ro) | 2019-09-30 |
Family
ID=59859424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190027T MD3416631T2 (ro) | 2016-08-11 | 2017-08-11 | Agenți terapeutici pentru bolile neurodegenerative |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US12144792B2 (enExample) |
| EP (3) | EP3583940A1 (enExample) |
| JP (3) | JP6957602B2 (enExample) |
| KR (4) | KR20220093385A (enExample) |
| CN (3) | CN109789114A (enExample) |
| AU (3) | AU2017308865B2 (enExample) |
| BR (1) | BR112019002730A2 (enExample) |
| CA (1) | CA3033564A1 (enExample) |
| CY (1) | CY1121930T1 (enExample) |
| DK (1) | DK3416631T3 (enExample) |
| ES (1) | ES2733677T3 (enExample) |
| HR (1) | HRP20191055T1 (enExample) |
| HU (1) | HUE045043T2 (enExample) |
| IL (3) | IL264641B2 (enExample) |
| LT (1) | LT3416631T (enExample) |
| MA (2) | MA47521A (enExample) |
| MD (1) | MD3416631T2 (enExample) |
| ME (1) | ME03454B (enExample) |
| MX (3) | MX383499B (enExample) |
| PL (1) | PL3416631T3 (enExample) |
| PT (1) | PT3416631T (enExample) |
| RS (1) | RS59048B1 (enExample) |
| RU (1) | RU2756519C2 (enExample) |
| SG (1) | SG11201901063SA (enExample) |
| SI (1) | SI3416631T1 (enExample) |
| SM (1) | SMT201900370T1 (enExample) |
| TN (1) | TN2019000033A1 (enExample) |
| WO (1) | WO2018029658A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| EP3313517B1 (en) | 2015-06-24 | 2023-06-07 | The Regents Of The University Of Michigan | Histotripsy therapy systems for the treatment of brain tissue |
| MD3416631T2 (ro) | 2016-08-11 | 2019-09-30 | Intrabio Ltd | Agenți terapeutici pentru bolile neurodegenerative |
| RS58478B1 (sr) | 2016-08-11 | 2019-04-30 | Intrabio Ltd | Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| IL273929B2 (en) * | 2017-10-18 | 2024-11-01 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
| DK3752141T3 (da) * | 2018-02-15 | 2024-07-15 | Intrabio Ltd | Acetyl-leucin til anvendelse til behandling af restless legs syndrom |
| CA3122223A1 (en) * | 2018-12-06 | 2020-06-11 | Intrabio Ltd | Deuterated analogs of acetyl-leucine |
| EP3934637B1 (en) * | 2019-03-02 | 2024-07-31 | IntraBio Ltd | (n-)acetyl-l-leucine for use in treating traumatic brain injury |
| CN114727761A (zh) * | 2019-09-17 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 患有运动障碍的患者的个性化保健的改善 |
| US20230051742A1 (en) * | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| EP4608504A1 (en) | 2022-10-28 | 2025-09-03 | Histosonics, Inc. | Histotripsy systems and methods |
| AU2024257180A1 (en) | 2023-04-20 | 2025-09-18 | Histosonics, Inc. | Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy |
| WO2025151578A1 (en) * | 2024-01-12 | 2025-07-17 | Intrabio Inc. | N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies |
| WO2025163129A1 (en) * | 2024-02-01 | 2025-08-07 | Intrabio Ltd. | Acetyl-leucine for treating parkinson´s disease |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| FR2905600B1 (fr) | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| EP2946779A1 (en) | 2007-02-22 | 2015-11-25 | Beiersdorf AG | Cosmetic and pharmaceutical applications of n-acetylhydroxyproline |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| SG10201810496XA (en) * | 2013-10-28 | 2018-12-28 | Naurex Inc | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| KR102791288B1 (ko) | 2016-04-19 | 2025-04-03 | 인트라바이오 리미티드 | 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 |
| MD3416631T2 (ro) | 2016-08-11 | 2019-09-30 | Intrabio Ltd | Agenți terapeutici pentru bolile neurodegenerative |
-
2017
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/me unknown
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en not_active Ceased
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/en active Pending
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/en active Pending
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP2022003085A/ja active Pending
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
-
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
-
2025
- 2025-03-21 AU AU2025202077A patent/AU2025202077A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201692436A1 (ru) | Медицинское применение | |
| UA118149C2 (uk) | Інгібітор jak | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX385687B (es) | Inhibidores de calicreína plasmática humana. | |
| MX379245B (es) | Compuesto de tres ciclos y aplicaciones del mismo | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX2022007315A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
| EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
| MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| CY1122375T1 (el) | Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer | |
| MX381932B (es) | Composicion intranasal que comprende betahistina. | |
| MX374354B (es) | Método de curación de heridas. |